Executive Summary
NASA's $109.2M obligation to Caltech (ceiling $125.4M) for JPL FFRDC operations and EMIT Earth mineral dust project through 2028 reflects sustained space R&D funding, with $90.3M already outlayed. Neutral signal due to nonprofit recipient limits direct equity exposure for investors. Minor upside from $16.2M unexercised options and potential future task orders warrants monitoring JPL ecosystem.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior NASA & Space Contracts Intelligence digest from February 28, 2026.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Long 10-year performance period to 2028-09-30 with full obligation dependent on future task orders issued by NASA Management Office -- JPL.
Opportunities (1)
- ◆
$16.2M unexercised options to reach $125.4M ceiling, plus continued JPL FFRDC sponsorship enabling additional NASA task orders through 2028.
Sector Themes (1)
- ◆
Non-competed $109.2M delivery order to Caltech/JPL under NAICS 541715 for EMIT and operations highlights NASA's dependence on FFRDCs for space science.
Watch List (1)
- 👁
{"entity"=>"Jet Propulsion Laboratory (JPL)", "reason"=>"Core FFRDC with $125.4M ceiling through 2028 and $90.3M outlayed, positioned for ongoing NASA space science tasks.", "trigger"=>"New task orders or option exercises exceeding $109.2M obligation"}
Get daily alerts with 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: NASA & Space Contracts Intelligence
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals